Roivant Sciences Ltd. (ROIV)

Market Cap	20.19B +171.0%
Revenue (ttm)	13.31M -56.4%
Net Income	-809.24M
EPS	-1.17
Shares Out	715.70M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,126,934
Open	28.48
Previous Close	28.48
Day's Range	27.95 - 28.54
52-Week Range	9.24 - 30.33
Beta	1.21
Analysts	Strong Buy
Price Target	27.56 (-2.3%)
Earnings Date	May 28, 2026

About ROIV

Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody that targets the neonatal fragment crystallizable receptor for the treatment of graves’ disease, difficult-to-treat rheumatoid arthritis, sjögren’s disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monocl...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2014
• Employees: 750
• Stock Exchange: NASDAQ
• Ticker Symbol: ROIV
• Website: https://roivant.com

Analyst Summary

According to 8 analysts, the average rating for ROIV stock is "Strong Buy." The 12-month stock price target is $27.56, which is a decrease of -2.30% from the latest price.

Price Target

$27.56

(-2.30% downside)

Analyst Consensus: Strong Buy